Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2007

View Archived Issues

Chloroquine to be evaluated for the treatment of metabolic syndrome / News in Context

Anxiety treatment with tandospirone improves atopic dermatitis

New targeted topical cream treatment shows promise in preclinical models of psoriasis

New therapeutic agents for renal-urological disorders disclosed in recent patents

Novel agents for treating neurological disorders revealed in patent literature

Recent patents describe possible new treatment options for diabetes

Quest Group International acquires new oncology product candidates

Phase III program planned for bapineuzumab in Alzheimer's

FDA awards orphan drug status to Ardana's oral growth hormone secretagogue

CUV-1647 begins phase III study in polymorphic light eruption

Tripep prepares for phase I/II study of ChronVac-C

Early close for tibolone study in breast cancer

Helsinn supports safety of nimesulide

New study compares safety of drug-eluting stents

KineMed evaluates mechanism of action of colesevelam in type 2 diabetes

CytRx updates operational activities

Talabostat clinical program placed on hold

CMC Biopharmaceuticals to support development of MORAb-028

Domain antibody PN-0621 begins phase I trial

MyVax studied in follicular NHL in phase II trial

AD-923 successfully completes pharmacokinetic study

Antigenics offers summary of Q1 events

Faster and prolonged acid suppression with AGN-201904-Z, an omeprazole prodrug

Amoxicillin PULSYS NDA accepted for filing

Lybrel receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...